Cargando…
Total Facial Autologous Fat Grafting for Treating Skin Manifestations in Scleroderma
Systemic sclerosis (SSc) or scleroderma, is a rare, systemic autoimmune connective tissue disease that can cause fibrosis of cutaneous tissue and visceral organs. Facial involvement can have a deleterious effect on patients’ function, cosmetic appearance and quality of life. This study describes our...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9783901/ https://www.ncbi.nlm.nih.gov/pubmed/36556362 http://dx.doi.org/10.3390/life12121997 |
_version_ | 1784857683979927552 |
---|---|
author | Berl, Ariel Shir-az, Ofir Perk, Noa Levy, Abraham Levy, Yair Shalom, Avshalom |
author_facet | Berl, Ariel Shir-az, Ofir Perk, Noa Levy, Abraham Levy, Yair Shalom, Avshalom |
author_sort | Berl, Ariel |
collection | PubMed |
description | Systemic sclerosis (SSc) or scleroderma, is a rare, systemic autoimmune connective tissue disease that can cause fibrosis of cutaneous tissue and visceral organs. Facial involvement can have a deleterious effect on patients’ function, cosmetic appearance and quality of life. This study describes our experience and results with total facial autologous fat grafting for treating scleroderma. It includes 14 women and 3 men with SSc, at an average age of 51.3 years who underwent 32 autologous fat grafting surgeries between 2017–2022. The surgical technique is further described and demographic and surgical data, including preoperative and postoperative measurements were analyzed. Patients who had multiple surgeries ultimately received grafts with twice the volume of fat than in the first procedure. The oral opening increased an average of 33%. All patients reported improvement in quality of life and were very satisfied with the aesthetic outcomes. The use of autologous fat grafting to treat SSc patients successfully increased oral openings and improved facial manifestations. The procedure is reproducible, safe and leads to improvement in facial manifestations and patients’ quality of life. It can be repeated over time to preserve or enhance the results. |
format | Online Article Text |
id | pubmed-9783901 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-97839012022-12-24 Total Facial Autologous Fat Grafting for Treating Skin Manifestations in Scleroderma Berl, Ariel Shir-az, Ofir Perk, Noa Levy, Abraham Levy, Yair Shalom, Avshalom Life (Basel) Article Systemic sclerosis (SSc) or scleroderma, is a rare, systemic autoimmune connective tissue disease that can cause fibrosis of cutaneous tissue and visceral organs. Facial involvement can have a deleterious effect on patients’ function, cosmetic appearance and quality of life. This study describes our experience and results with total facial autologous fat grafting for treating scleroderma. It includes 14 women and 3 men with SSc, at an average age of 51.3 years who underwent 32 autologous fat grafting surgeries between 2017–2022. The surgical technique is further described and demographic and surgical data, including preoperative and postoperative measurements were analyzed. Patients who had multiple surgeries ultimately received grafts with twice the volume of fat than in the first procedure. The oral opening increased an average of 33%. All patients reported improvement in quality of life and were very satisfied with the aesthetic outcomes. The use of autologous fat grafting to treat SSc patients successfully increased oral openings and improved facial manifestations. The procedure is reproducible, safe and leads to improvement in facial manifestations and patients’ quality of life. It can be repeated over time to preserve or enhance the results. MDPI 2022-11-30 /pmc/articles/PMC9783901/ /pubmed/36556362 http://dx.doi.org/10.3390/life12121997 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Berl, Ariel Shir-az, Ofir Perk, Noa Levy, Abraham Levy, Yair Shalom, Avshalom Total Facial Autologous Fat Grafting for Treating Skin Manifestations in Scleroderma |
title | Total Facial Autologous Fat Grafting for Treating Skin Manifestations in Scleroderma |
title_full | Total Facial Autologous Fat Grafting for Treating Skin Manifestations in Scleroderma |
title_fullStr | Total Facial Autologous Fat Grafting for Treating Skin Manifestations in Scleroderma |
title_full_unstemmed | Total Facial Autologous Fat Grafting for Treating Skin Manifestations in Scleroderma |
title_short | Total Facial Autologous Fat Grafting for Treating Skin Manifestations in Scleroderma |
title_sort | total facial autologous fat grafting for treating skin manifestations in scleroderma |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9783901/ https://www.ncbi.nlm.nih.gov/pubmed/36556362 http://dx.doi.org/10.3390/life12121997 |
work_keys_str_mv | AT berlariel totalfacialautologousfatgraftingfortreatingskinmanifestationsinscleroderma AT shirazofir totalfacialautologousfatgraftingfortreatingskinmanifestationsinscleroderma AT perknoa totalfacialautologousfatgraftingfortreatingskinmanifestationsinscleroderma AT levyabraham totalfacialautologousfatgraftingfortreatingskinmanifestationsinscleroderma AT levyyair totalfacialautologousfatgraftingfortreatingskinmanifestationsinscleroderma AT shalomavshalom totalfacialautologousfatgraftingfortreatingskinmanifestationsinscleroderma |